Author:
Kasper B.,Sleijfer S.,Litière S.,Marreaud S.,Verweij J.,Hodge R.A.,Bauer S.,Kerst J.M.,van der Graaf W.T.A.
Reference19 articles.
1. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas;Kasper;Future Oncol,2011
2. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy;Blay;Eur J Cancer,2003
3. Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2 pyrimidinyl]amino] 2 methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor;Harris;J Med Chem,2008
4. Phase I trial of pazopanib (GW786034), an oral multikinase angiogenesis inhibitor, in patients with advanced cancer: results of safety, pharmacokinetics, and clinical activity;Hurwitz;Clin Cancer Res,2009
5. Pazopanib—the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma;Keisner;Drugs,2011
Cited by
96 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献